Market Cap
$1.5B
MAZE
Maze Therapeutics, Inc.
$27.18 ▲ +1.99%
Prev close $26.65Market cap$1.5B
ConsensusStrong Buy
12-mo target$61.50 (+126.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)38 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MAZE right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$771.9M
Inst. Activity
38 buys / 11 sells
Insider Activity
$0.00 buy / $7.1M sell
Insider Net $
-$7.1M
SEC Reports
18
Press Releases
1
Price chart 30d +1.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 Insider
Dandekar Atul acquired via exercise 7,500 shares
CSBO @ $10.42 ($78.2K)
Sep 29, 2026 Insider
Dandekar Atul sold 7,500 shares
CSBO @ $27.06 ($202.9K)
Sep 28, 2026 short_volume
Sep 5, 2026 SEC Short Volume: MAZE — 70.6% short (0.4M / 0.6M)
Short: 420,437 | Exempt: 0 | TRF Vol: 595,135 | Short Ratio: 70.6% | Off-exchange volume (dark pool
Four top Maze Therapeutics insiders — CEO, President/R&D/CMO, GC, and CSBO — sold a combined ~$498K in open-market share
CLUSTER — Impact 2/10
Three top executives at Maze Therapeutics (CEO, President R&D, CSBO) sold a combined ~$1.46M in shares over a three-day
CLUSTER — Impact 3/10
Insider cluster at Maze Therapeutics shows CEO Jason Coloma and CSBO Atul Dandekar selling small amounts of stock over a
CLUSTER — Impact 2/10
Sep 4, 2026 Insider
Bernstein Harold sold 9,705 shares
President, R&D & CMO @ $26.22 ($254.5K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
3,502,841 shares ($104.5M)
Analyst ratings buy % +2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 23, 2026 | Citigroup | INITIATE | Buy | 55% |
| Sep 23, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 22, 2026 | BTIG | REITERATE | Buy | 53% |
| Aug 12, 2026 | BTIG | REITERATE | Buy | 53% |
| Apr 14, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Price targets
Where 12 covering analysts think MAZE trades over the next 12 months.
$61.50 +126.3% upside Strong Buy
Current$27.18 Low$46.00 Median$54.00 High$110.00 12 analysts
$46.00$110.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 15 neutral · avg impact 3.2/10.Plus 1 press releases.
NEUTRALCLUSTER2/10
Four top Maze Therapeutics insiders — CEO, President/R&D/CMO, GC, and CSBO — sold a combined ~$498K
Sep 5, 2026
NEUTRALCLUSTER3/10
Three top executives at Maze Therapeutics (CEO, President R&D, CSBO) sold a combined ~$1.46M in shar
Sep 4, 2026
NEUTRALCLUSTER2/10
Insider cluster at Maze Therapeutics shows CEO Jason Coloma and CSBO Atul Dandekar selling small amo
Sep 4, 2026
NEUTRAL1442/10
Two officers of Maze Therapeutics filed Form 144 notices on September 2, 2026, indicating intent to
Sep 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: MAZE — 70.6% short (0.4M / 0.6M)
Short: 420,437 | Exempt: 0 | TRF Vol: 595,135 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: MAZE — 64.4% short (0.6M / 0.9M)
Short: 574,857 | Exempt: 1,861 | TRF Vol: 893,072 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: MAZE — 55.4% short (0.4M / 0.8M)
Short: 433,126 | Exempt: 0 | TRF Vol: 781,860 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Aug 18, 2026
earnings_calendar
MAZE Q2 2026 Earnings Scheduled — 2026-08-18
Aug 13, 2026
other
Maze Therapeutics Announces Appointments to Its Board of Directors
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical an
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.76 | $-0.87–$-0.56 | -15.1% | -1.9% | 3↑ 4↓ | $0.0B | 9 |
| Next Q | $-0.80 | $-0.94–$-0.57 | -23.2% | -2.2% | 4↑ 3↓ | $0.0B | 9 |
| Current FY | $-2.76 | $-3.06–$-2.07 | 9.5% | -1.2% | 3↑ 3↓ | $0.0B | 9 |
| Next FY | $-3.30 | $-4.28–$-2.31 | -19.5% | -3.9% | 4↑ 3↓ | $0.0B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.760 | — |
| 7d ago | $-0.746 | -0.014 |
| 30d ago | $-0.746 | -0.014 |
| 60d ago | $-0.749 | -0.010 |
| 90d ago | $-0.749 | -0.010 |
Institutional ownership
Which big funds own MAZE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $771.9M total value (25,898,388 shares) as of 2026-Q2. Top holders: BlackRock,, Jupiter, VANGUARD. Net buying activity: 38 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,502,841 | $104.5M | 13.5% | ADD +36.3% |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 13.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,778,222 | $53.1M | 6.9% | — |
| a16z Capital Management, L.L.C. | 1,702,225 | $50.8M | 6.6% | — |
| Alphabet Inc. | 1,388,583 | $41.4M | 5.4% | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1,107,814 | $33.1M | 4.3% | DOUBLED +197.0% |
| FMR LLC | 1,056,959 | $31.5M | 4.1% | — |
| STATE STREET CORP | 997,533 | $29.8M | 3.9% | ADD +56.7% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 954,886 | $28.5M | 3.7% | ADD +50.1% |
| JPMORGAN CHASE & CO | 964,011 | $28.0M | 3.6% | DOUBLED +1549.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 2,570,425 | 3,502,841 | +36.3% | $104.5M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | DOUBLED | 373,000 | 1,107,814 | +197.0% | $33.1M |
| STATE STREET CORP | ADD | 636,722 | 997,533 | +56.7% | $29.8M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 636,162 | 954,886 | +50.1% | $28.5M |
| JPMORGAN CHASE & CO | DOUBLED | 58,446 | 964,011 | +1549.4% | $28.0M |
| MARSHALL WACE, LLP | DOUBLED | 310,639 | 914,572 | +194.4% | $27.3M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 599,967 | 858,054 | +43.0% | $25.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 195,542 | 393,107 | +101.0% | $11.7M |
| Aberdeen Group plc | ADD | 226,227 | 383,773 | +69.6% | $11.5M |
| BANK OF AMERICA CORP /DE/ | ADD | 195,084 | 321,227 | +64.7% | $9.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 50 transactions. Net -$7.1M — $0.00 bought, $7.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Dandekar Atul | CSBO | EXERCISE | 7,500 | $10.42 | $78.2K |
| Sep 29, 2026 | Dandekar Atul | CSBO | SELL | 7,500 | $27.06 | $202.9K |
| Sep 4, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 9,705 | $26.22 | $254.5K |
| Sep 3, 2026 | Courtney Phillips | GC and Corp. Secretary | SELL | 22 | $25.78 | $567.16 |
| Sep 3, 2026 | Courtney Phillips | GC and Corp. Secretary | SELL | 1,990 | $26.01 | $51.8K |
| Sep 3, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 59 | $25.78 | $1.5K |
| Sep 3, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 5,130 | $26.01 | $133.4K |
| Sep 3, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 129 | $25.77 | $3.3K |
| Sep 3, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 11,282 | $26.01 | $293.5K |
| Sep 3, 2026 | Dandekar Atul | CSBO | SELL | 36 | $25.81 | $929.16 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MAZE.
Shares short
5,678,289
Settlement Sep 15, 2026
Change vs prior
-4.1%
Semi-monthly cycle
Days to cover
10.4
At avg daily volume
Of shares outstanding
≈10.2%
Estimate — not % of float
All MAZE filing & press-release reports (19)
- CLUSTER reportSep 5, 2026
- CLUSTER reportSep 4, 2026
- CLUSTER reportSep 4, 2026
- 144 reportSep 2, 2026
- 144 reportSep 1, 2026
- 3 reportAug 17, 2026
- PRESS-RELEASE reportAug 11, 2026
- INST-CLUSTER reportAug 7, 2026
- CLUSTER reportAug 6, 2026
- CLUSTER reportJul 3, 2026
- CLUSTER reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 3, 2026
- 8-K reportMay 22, 2026
- CLUSTER reportMay 18, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 424B5 reportApr 22, 2026
- PRESS-RELEASE reportMar 25, 2026